ExpertiseUpdated on 26 June 2025
Preclinical Immuno-Modulatory Drug Development in Oncology
About
Abbmira has amassed significant pre-clinical data demonstrating that its experimental small molecule compounds enhance anticancer activity in relevant mouse models via macrophage re-programming. Compound42 binds to a defined intracellular target in tumor associated macrophages (TAMs), which activates these native immune cells to generate an anti-tumor microenvironment.
Field
- CHE - Chemistry
- LIF - Life Sciences
- POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements
- DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings
Organisation
Similar opportunities
Project cooperation
Preclinical Immuno-modulatory Drug Development in Oncology
- MSCA-PF2025
- MSCA-DN2025
- Proposal Idea
- Proposal under Development
- POSTDOCTORAL FELLOWSHIP: Looking for an Institution for Secondment
- DOCTORAL NETWORK: Looking for Partner/s (Beneficiaries or Associated Partners)
Marc Creus
CEO at abbmira therapeutics AG
Basel, Switzerland
Expertise
Numerical seabed using hydroacoustic digital twins
- MAT - Mathematics
- DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings
- POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements
Andrés Prieto
Professor at Galician Center of Mathematical Research and Technology
A Coruña, Spain
Expertise
Maximizing funding opportunities: 1 Proposal = 5 Calls
- CHE - Chemistry
- POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements
Vladislav Ivanistsev
Associate Professor at University of Latvia
Riga, Latvia